CARsgen Therapeutics Holdings Ltd. (HK:2171) has released an update.
CARsgen Therapeutics Holdings Ltd. has announced the publication of promising final results from their Phase 1 trial of satri-cel, a pioneering CAR T-cell therapy targeting Claudin18.2 positive tumors, in Nature Medicine and at the ASCO Annual Meeting. Satri-cel, which is being developed for gastric and pancreatic cancers, has achieved significant regulatory designations, including RMAT from the U.S. FDA and PRIME eligibility from the EMA, highlighting its potential as a first-in-class therapy. The company, with operations in both China and the U.S., is committed to advancing innovative CAR T-cell therapies for a variety of cancers.
For further insights into HK:2171 stock, check out TipRanks’ Stock Analysis page.
